Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Pathology Department, General Medicine Practice, Batterjee Medical College, Jeddah, Saudi Arabia.
J Evid Based Integr Med. 2023 Jan-Dec;28:2515690X231198315. doi: 10.1177/2515690X231198315.
Some epithelial tumors express the carbohydrate antigen 125 (Cancer antigen-125, CA-125) and CA 19-9, especially ovarian and pancreatic tumors. Patients with non-Hodgkin lymphoma (NHL) were reported to have a close association between serum CA-125 levels and adverse prognostic factors with worse survival. We aimed to investigate CA-125 and 19-9 expression in nodal diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS) tissues using immunohistochemistry (IHC) and their relations to clinicopathological manifestations and patients' survival. 65 cases of DLBCL NOS were examined. A modified mechanical pencil tip was used to construct Manual Tissue Micro-array TMA) blocks. Immunohistochemical staining for CA-125 and CA 19-9 was performed and scored semi-quantitatively. All relations were analyzed using established statistical methodologies. Aberrant expression of CA 19-9 was detected in 12% of cases without any expression of CA-125. Moreover, 75% of the CA 19-9 positive cases were statistically significantly associated with anemia and performance status 1. Also, 75% of the CA 19-9 positive cases were females. CA 19-9 was aberrantly expressed in 12% of nodal DLBCL NOS cases and significantly related to anaemia and performance status but not to survival. In cases of DLBCL NOS, CA 19-9 expression cannot be considered an independent prognostic factor. CA-125 was not expressed in nodal DLBCL NOS tissues, necessitating re-evaluation studies. Therefore, it is advised to conduct more research to clarify the potential correlation between serum and tissue CA 19-9 levels and other clinic-pathological characteristics of nodal and extranodal DLBCL NOS patients.
一些上皮性肿瘤表达碳水化合物抗原 125（Cancer antigen-125，CA-125）和 CA 19-9，尤其是卵巢和胰腺肿瘤。有报道称，非霍奇金淋巴瘤（NHL）患者的血清 CA-125 水平与不良预后因素密切相关，生存状况较差。我们旨在通过免疫组织化学（IHC）检测结内弥漫性大 B 细胞淋巴瘤，非特指型（DLBCL NOS）组织中 CA-125 和 19-9 的表达，并研究其与临床病理表现和患者生存的关系。 检查了 65 例 DLBCL NOS。使用改良的机械铅笔尖构建手动组织微阵列（TMA）块。进行 CA-125 和 CA 19-9 的免疫组织化学染色，并进行半定量评分。使用既定的统计方法分析所有关系。 12%的病例检测到 CA 19-9 异常表达，而无 CA-125 表达。此外，75%的 CA 19-9 阳性病例与贫血和体能状态 1显著相关。而且，75%的 CA 19-9 阳性病例为女性。 CA 19-9 在 12%的结内 DLBCL NOS 病例中异常表达，与贫血和体能状态显著相关，但与生存无关。在 DLBCL NOS 病例中，CA 19-9 表达不能被认为是独立的预后因素。在结内 DLBCL NOS 组织中未检测到 CA-125 表达，需要重新评估研究。因此，建议进行更多的研究，以阐明血清和组织 CA 19-9 水平与结内和结外 DLBCL NOS 患者的其他临床病理特征之间的潜在相关性。
